Skip to main content
SpringerLink
Log in

Bulevirtide: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Bulevirtide (Hepcludex®), a first-in-class entry inhibitor, is being developed by MYR GmbH for the treatment of chronic hepatitis delta virus (HDV) and chronic hepatitis B virus (HBV) infections. Bulevirtide was recently approved in the European Union (EU) for the treatment of chronic HDV infection in HDV RNA positive adult patients with compensated liver disease. This article summarizes the milestones in the development of bulevirtide leading to this first approval for chronic HDV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. MYR Pharmaceuticals. MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX® [media release]. 4 Aug 2020. https://www.prnewswire.com.

  2. European Medicines Agency. Hepcludex (bulevirtide) powder for solution for injection: EU summary of product characteristics. 2020. https://ec.europa.eu. Accessed 31 Aug 2020.

  3. Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor Myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490–8.

    Article  CAS  Google Scholar 

  4. Blank A, Markert C, Hohmann N, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor Myrcludex B. J Hepatol. 2016;65(3):483–9.

    Article  CAS  Google Scholar 

  5. European Medicines Agency. Hepcludex: EPAR—medicine overview. 2020. https://www.ema.europa.eu. Accessed 31 Aug 2020.

  6. MYR Pharmaceuticals. MYR Pharmaceuticals—treatment of HBV & HDV infections. 2020. https://myr-pharma.com. Accessed 31 Aug 2020.

  7. Maxwell Biotech Venture Fund. Maxwell Biotech Venture Fund invests in hepatitis B/D clinical program [media release]. 15 Mar 2012. https://www.rvc.ru.

  8. Volz T, Allweiss L, Ben MM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58(5):861–7.

    Article  CAS  Google Scholar 

  9. European Medicines Agency. Hepcludex: EU assessment report. 2020. https://www.ema.europa.eu. Accessed 31 Aug 2020.

  10. Wedemeyer H, Bogomolov P, Blank A, et al. Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with tenofovir in patients with chronic HBV/HDV co-infection [abstract no. GS-005]. J Hepatol. 2018;68(Suppl 1):S3.

  11. Wedemeyer H, Schoneweis K, Bogomolov PO, et al. Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in with PEG-interferon alpha 2a in patients with chronic HBV/HDV co-infection [abstract no. GS-13]. J Hepatol. 2019;70(1):e81.

  12. Wedemeyer H, Schoneweis K, Bogomolov P, et al. Safety and efficacy of 10mg (high-dose) bulevirtide (Myrcludex B) in combination with PEG-interferon alpha 2a or tenofovir in patients with chronic HBV/ HDV co-infection: week 24 interim results of the MYR203 extension study [abstract no. 85]. Hepatology. 2019;70(Suppl 1):58A-9A.

  13. Haag M, Hofmann U, Mürdter TE, et al. Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring epatitis B therapy by a novel Na+-taurocholate cotransporting polypeptide inhibitor. Anal Bioanal Chem. 2015;407:6815–25.

    Article  CAS  Google Scholar 

  14. Hepatera. Maxwell Biotech portfolio company Hepatera announces proof-of-concept clinical results with Myrcludex B, a novel entry inhibitor for treatment of chronic hepatitis B and Delta [media release]. 21 Oct 2014. https://www.hepatera.ru.

Download references

Acknowledgements

During the peer review process the manufacturer of the agent under review was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Connie Kang & Yahiya Y. Syed

Authors
  1. Connie Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yahiya Y. Syed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Connie Kang.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest

Connie Kang and Yahiya Y. Syed are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability

Not applicable.

Additional information

Enhanced material for this AdisInsight Report can be found at https://doi.org/10.6084/m9.figshare.12806612.

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kang, C., Syed, Y.Y. Bulevirtide: First Approval. Drugs 80, 1601–1605 (2020). https://doi.org/10.1007/s40265-020-01400-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-020-01400-1

Search

Navigation